Tratamento cirúrgico da otosclerose na residência médica Surgical treatment of otosclerosis in medical residency training

A proporção de pacientes com otosclerose estapediana em relação ao número de otorrinolaringologistas tem diminuído nos últimos anos. Questiona-se se a cirurgia de tratamento da otosclerose deve ou não continuar sendo ensinada para residentes. OBJETIVO: Avaliar os resultados e complicações das estapedotomias realizadas por residentes no período de janeiro de 1997 a janeiro de 2000; verificar a inclusão da estapedotomia no programa de residência médica. FORMA DE ESTUDO: Estudo de coorte histórica longitudinal. MATERIAIS E MÉTODOS: Avaliados 50 prontuários de pacientes submetidos a um total de 51 estapedotomias quanto às complicações e resultados audiológicos. RESULTADOS: Fechamento do gap aéreo-ósseo para menor ou igual a 10dB NA em 70,5% das orelhas e menor ou igual a 20 dB NA em 86,3% das orelhas. Ocorreu 1 caso de surdez total. Complicações: subluxação da bigorna (7,8%), perfuração da membrana timpânica (5,8%), vertigem incapacitante que se resolveu dentro de 3 semanas (5,8%), otorréia (3,9%), platina flutuante (1,95) e fístula perilinfática (1,9%). CONCLUSÃO: A análise da literatura e os resultados e complicações obtidos neste estudo permitem concluir que a estapedotomia pode ser incluída no programa de residência médica, desde que haja disponibilidade de casos cirúrgicos para o treinamento dos residentes.<br>The number of patients with stapes otosclerosis compared to the number of otorhinolaryngologists has declined over the past several years. As a result a controversy has arisen in the literature, whether or not stapes surgery should be included in residency programs. AIM: the objective of the present study is to evaluate the results and complications of estapedotomies performed by residents between January, 1997 and January, 2000, and consequently study the feasibility of including estapedotomies in residency programs. STUD DESIGN: retrospective review of prospectively collected audiometric data. MATERIALS AND METHODS: fifty charts of patients that were submitted to a total of 51 primary stapedotomies were reviewed mainly for complications and audiological results. RESULTS: there was closure of the air-bone gap within 10 dB HL in 70.5% of ears and closure to within 20 dB HL in 86.3% of ears. There was one ear with total hearing loss (2%). CONCLUSION: From the results and complications seen in the present study, and analyzing papers from the literature, it is possible to conclude that stapedotomy is a procedure that can be included in residency programs, if there are surgical cases for the residents

Adjuvant chemotherapy in completely resected gastric cancer: A Randomized phase III trial conducted by GOIRC

Background Complete surgical resection of gastric cancer is potentially curative, but long-term survival is poor. Methods Patients with histologically proven adenocarcinorna of the stomach of stages IB, II, IIIA and B, or IV (T4N2MO) and treated with potentially curative surgery were randomly assigned to follow-up alone or to intravenous treatment with four cycles (repeated every 21 days) of PELF (cisplatin [40 mg/m(2), on days 1 and 5], epirubicin [30 mg/m(2), days 1 and 5], L-leucovorin [100 mg/m(2), days 1-4], and 5-fluorouracil [300 mg/m(2), days 1-41 in a hospital setting. Frequencies and severity of adverse events were determined. Overall survival (OS) and disease-free survival (DFS) were compared between the treatment arms using Kaplan-Meier analysis and a Cox proportional hazards regression model. All statistical tests were two-sided. Results From January 1995 through September 2000, 258 patients were randomly assigned to chemotherapy (n = 130) or surgery alone (n = 128). Patient characteristics were well balanced between the two arms. Among those who received chemotherapy, grade 3 or 4 toxic effects including vomiting, mucositis, and diarrhea were experienced by 21.1%, 8.4%, and 11.8% of patients, respectively. Leucopenia, anemia, and thrombocytopenia of grade 3 or 4 were experienced by 20.3%, 3.3%, and 4.2% of patients, respectively. After a median follow-up of 72.8 months, 128 patients (49.6%) experienced recurrence and 139 (53.9%) deaths were observed, one toxicity-related. Relative to treatment with surgery alone, adjuvant chemotherapy did not increase disease-free survival (hazard ratio [HR] of recurrence = 0.92; 95% confidence interval [CI] 0.66 to 1.27) or overall survival (HR of death = 0.90; 95% Cl = 0.64 to 1.26). Conclusions Our results failed to provide proof of an effect of adjuvant chemotherapy with PELF on overall survival or disease-free survival. The estimated effect of chemotherapy (10% reduction in the hazard of death or relapse) is modest and consistent with the results of meta-analyses of adjuvant chemotherapy without platinum agents